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REVIEW ARTICLE 
THE CRADLE OF THE ΔF508 MUTATION 
Danish Saleheen1,2, Philippe M. Frossard1 
1 Department of Biological and Biomedical Sciences, Aga Khan University, Stadium Road, Karachi, Pakistan.  
2Molecular Epidemiology Unit, Strangeways Research Labs, Department of Public Health and Primary Care, University of Cambridge, 
Cambridge, UK 
Cystic fibrosis (CF) is the most common autosomal recessive disorder caused due to mutation/s in 
the CFTR gene. The most common mutation in CFTR worldwide is ΔF508 and cystic fibrosis 
genetic analysis consortium revealed that this mutation is responsible for approximately 66% of all 
CF chromosomes in the world. Studies looking at the DNA polymorphic haplotypes created by CF 
linked markers suggest that ΔF508 has a single origin as this mutation has been found associated 
exclusively with one marker haplotype. Despite a high prevalence of this mutation in CF patients 
in northern parts of Europe, findings suggest that this mutation was not spread by Europeans but 
by a group that is speculated to have originated in the Middle East or a more eastern region in Asia 
(most likely subcontinent). Over here we have given a brief introduction to cystic fibrosis and 
classification of CFTR mutations and have further elaborated on the crucial issue about the spread 
of the ΔF508 mutation. We have reviewed findings that give clues about the origin of this 
mutation from the Baluch ethnicity residing in Pakistan. 
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Cystic fibrosis (CF) is the most common life-limiting 
autosomal recessive disorder; it affects nearly 1/2500 
live births in Caucasians.1 CF is a multi-system disease 
and can involve secretory cells, sinuses, lungs, 
pancreas, liver and the reproductive tract.1 The disease 
has a “classical” appearance in 90% of cases and 
patients present with a triad of chronic obstructive 
pulmonary disease, exocrine pancreatic insufficiency 
and elevation of sodium and chloride concentrations in 
the sweat.1–3 After extensive research in the field, in 
western countries, 60% of all CF patients have a 
diagnosis of the disease before their first birthday and 
90% of all CF patients are diagnosed by 10 years of 
age. This has greatly affected the life expectancy of CF 
patients as compared to the past.1 
The first evidence of CF being a monogenic 
disorder came from the reviews of CF pedigrees in 
Italian church records in 1985.2 Later on identification 
and cloning of the CFTR gene on chromosome 7 
served as the basis for understanding the genetic 
aetiology of the disease.4–5 The gene causing CF spans 
190 Kb of DNA and encodes a 1480 amino acid 
polypeptide named cystic fibrosis transmembrane 
regulator (CFTR).6 To date 1529 mutations have been 
identified in the gene.7 These mutations have a variety 
of effects at the cellular level. However they can be 
grouped into 6 categories8, in which they: 
i. block the synthesis of CFTR,  
ii. lead to defective processing 
iii. cause abnormal regulation of CFTR Cl channel  
iv. disrupt the normal conductive pathway of the 
channel  
v. lead to complete or partial production of CFTR 
protein 
vi. lead to defective regulation of other channels.  
The most common mutation in CFTR 
worldwide is ΔF508.1 It is a class II mutation caused 
by deletion of three bases encoding a phenylalanine 
residue at position 508 within the nucleotide binding 
domain (NBD).9 Heterologous expression system 
analyses have shown that this mutation results in mis-
folding of the CFTR and hence mislocalization and 
defective processing of the mature protein.9 It was 
postulated that the mutation is severe enough to result 
in absence of any mature protein in the affected 
cells.10 Recent immuno-cytochemical studies of 
intestinal, respiratory and hepatobiliary epithelia, 
however, show that in patients homozygous for Δ 
F508, a proportion of CFTR protein was shown to be 
targeted to the apical membranes.11 The fact was lent 
support by in vitro studies done on ΔF508 
homozygous CF patients suggesting that at least 
some CFTR molecules reach the plasma membrane 
in these patients.12 Genotype-phenotype correlations 
clearly indicate that this mutation is severe as far as 
pancreatic status is concerned but conclusions on its 
effect on lung disease vary between studies.8. 
Cystic fibrosis genetic analysis consortium 
revealed that ΔF508 is responsible for approximately 
66% of all CF chromosomes in the world.13 However 
its frequency varies from region to region.13 The 
highest frequency has been found in patients from 
Northern Europe, where it accounts for 75%-88% of 
all CF alleles.14 Indeed, the frequency reaches to a 
maximum of 100% in the isolated Faroe Islands of 
Denmark.15 Importantly, evaluation of studies that 
have been done on European populations reveal a 
clear-cut north-west to south-east gradient of ΔF508 
prevalence in CF patients showing a maximum 
prevalence of 88% in Denmark (excluding Faroe 
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islands) to a minimum of 24.5% in the Turkish 
population.13–15  
Although studies investigating the origin of 
ΔF508 have failed to identify any founder population 
but have established strong evidence in ruling out 
various potential regions (for eg. Faroe islands) 
where the mutation could have possibly 
originated.13,16–19 These DNA based studies normally 
utilize single nucleotide polymorphisms (SNP’s) and 
several short tandem repeat polymorphisms which 
are also known as ‘microsatellites’ within a gene of 
interest to find and trace the origin of a mutation. By 
utilizing such a methodology, evolutionary origin of 
some CF causing mutations have been identified; for 
instance CFTR mutation G542X had a single origin 
in the ancient Phoenicians.20 Similarly CFTR 
mutation G551D has been associated with Celtic 
tribes.21 
SNP’s or microsatellite markers by virtue of 
linkage disequilibrium can be used to create haplotypic 
maps. A haplotype containing a CFTR mutation or a 
SNP linked with a CFTR mutation displays a 
geographical gradient starting from a higher frequency 
in the founder population residing in a specific region 
to a lower frequency in a region where migration from 
the prior region has occurred lately. Based on this 
principle ancestry of a CFTR mutation G551D was 
revealed, as one particular haplotype containing this 
mutation remained unaltered from more than 170 
generations and displayed variable frequencies in 
different regions.20,22 
Studies looking at the DNA polymorphic 
haplotypes created by CF linked markers suggest that Δ 
F508 has a single origin.16 This mutation has been found 
associated exclusively with one marker haplotype. 
Morral et al.  have suggested that the original time of 
this mutation ranges from 3000 years to 53000 years 
ago.16 Despite a high prevalence in northern parts of 
Europe, findings suggest that the mutation is more 
ancient and did not originate in Europe.16–19 Moreover, 
analyses of wild type chromosome containing CFTR 
gene of various European populations suggest that the 
general genetic background of these populations is 
different than the diseased CFTR chromosome and thus 
the origin of most frequent CF mutations should be non-
European.17–18  
Based on these findings, Mateu et al. 
investigated the origins of five common CFTR 
mutations including ΔF508 in 949 unrelated 
autochthonous healthy individuals of various 
geographical origins and concluded that the haplotype 
containing ΔF508 was present in very low frequencies 
in the European populations.19 However, the highest 
frequency was detected in one Middle Eastern 
population.19 Although Mateu et al. did not report the 
data on the different Middle Eastern ethnicities, a 
comprehensive pattern of CF causing mutations in two 
Middle Eastern regions has been reported by Frossard 
et al.23,24 The data from Middle East show high 
frequencies of Δ F508 in particular ethnicities. Despite 
the fact that data reported by Frossard et al. does not 
show the haplotype frequencies, it is now widely 
believed that Δ F508 is more ancient and that it was 
not spread by Europeans but by a group that preceded 
them.16–19,21,23 This group is speculated to have 
originated in the “Middle East” or a more eastern 
region in Asia (most likely subcontinent).23,25 Thus it is 
important to study this mutation along with specific 
haplotypes in the CF patients of Middle East, Pakistani 
and Indian origin to discover more about its origins. 
Studies on CF in indigenous subcontinental 
population are severely lacking. Two studies have been 
done in this regard looking at the prevalence of ΔF508 
prevalence in CF patients. Both studies were done on 
patients who were admitted to tertiary care hospitals. In 
both the studies the patients were diagnosed of CF by 
pilocarpine iontophoresis test initially. Study done by 
Bhutta ZA et al on Pakistani population was limited to 
very small sample size.26 They evaluated 15 patients 
belonging to different ethnicities in Pakistan and found a 
60% prevalence of this mutation in the Pakistani CF 
population. The other study done by Kabra SK et al 
looked at a patient population coming from different 
regions of India and Pakistan. ΔF508 was identified in 
19% chromosomes out of 290 tested.27 It is surprising to 
note that ΔF508 was highest (56%) in patients of 
Pakistani origin as compared to a 12% prevalence of 
this mutation in Indian CF patients.27 Findings of both 
studies could be challenged on the fact that ΔF508 is a 
severe mutation as far as pancreatic status is concerned 
and patients carrying this mutation are hence more 
likely to be hospitalized compared to those with milder 
mutations, which would confer a spuriously high 
prevalence of ΔF508 in a hospital-based sample 
population. A 42% difference in prevalence between 
Pakistani and Indian CF populations, however, cannot 
be ignored.  
It must be kept in mind that the ‘Pakistani 
population’ does not have a homogenous distribution 
and is composed of people belonging to different 
ethnicities. It is highly essential to look at the individual 
ethnic data while studying the genetic mutation 
spectrum of a disorder like CF. Studies looking at the 
ΔF508 prevalence in CF patients of Pakistani origin 
living overseas have been variable and have looked at 
heterogeneous Pakistani populations rather than 
individual ethnicities. The most striking evidence of a 
high prevalence of ΔF508 in a Pakistani ethnic group 
comes from the findings of Frossard et al., who studied 
CF genetic mutations in the United Arab Emirates.23 
They investigated 17 unrelated families and found a 
86% prevalence (14/16 alleles) of ΔF508 in Baluchis 
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residing in UAE. Out of this Baluch population, all 
Pakistani Baluch CF patients carried ΔF508 mutation 
(100% prevalence). These findings were subsequently 
confirmed in the Omani population, in which 100% of 
CF patients of Baluch origin were also ΔF508 
homozygotes.24 Keeping in view the findings discussed 
earlier about a non-European origin of ΔF508 and a 
high prevalence of ΔF508 found in Pakistani Baluchis, 
it has been proposed that this mutation might have 
originally arisen in Baluchis. This hypothesis is 
analogous to the findings of Quaife et al.28 who studied 
the spectrum of beta-thalessemia in the UAE population 
and concluded that some specific mutations were 
introduced into UAE population by Baluchi immigrants.  
The Baluch ethnicity currently resides in Iran, 
Pakistan (Baluchistan) and Afghanistan, and its people 
are known to have immigrated through successive 
waves to the Punjab, India and Gulf countries (Oman 
and the UAE). However, the actual geographical 
location of Baluchis refers only to the western 
province of Pakistan, Baluchistan. To prove a founding 
effect of ΔF508 mutation in the Pakistani Baluch 
population, it is highly essential to study Baluchis of 
Pakistani province Baluchistan using appropriate 
haplotype analyses. This will answer the crucial 
question in the field of CF to know whether indeed 
‘Baluchistan’ was the cradle of the ΔF508 mutation. 
 
Figure-1: Starred line represents approximate 
boundaries of the Baluch ethnicity. The arrow 
indicates the migrations that occurred historically 
from Baluchistan to Oman and the UAE. 
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